Tenofovir-based oral preexposure prophylaxis prevents HIV in... : Current Opinion in HIV and
AIDS Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women …

Women and girls comprise nearly half of HIV-infected individuals globally and 20% of new
infections in the United States, indicating an urgent need to optimise HIV prevention options …

Introduction HIV incidence remains high among young women in sub‐Saharan Africa in
spite of scale‐up of HIV testing, behavioural interventions, antiretroviral treatment and …

Disproportionate rates of HIV are observed in Black women and men, especially in the
Southern United States. We observed limited uptake of preexposure prophylaxis (PrEP) …

Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence
and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable …

Background: FEM-PrEP—a clinical trial of daily, oral emtricitabine/tenofovir disoproxil
fumarate for HIV prevention among women in sub-Saharan Africa—did not show a reduction …

We aim to provide evidence-based guidance on best clinical practice in the provision,
monitoring and support of pre-exposure prophylaxis (PrEP) for the prevention of HIV …

Background: Adolescent girls and young women (AGYW) in sub-Saharan Africa have high
HIV prevalence and incidence. We sought to understand which HIV risk factors individually …

Background HIV risk perceptions are a key determinant of HIV testing. The success of efforts
to achieve an AIDS-free generation–including reaching the UNAIDS 90–90-90 target–thus …

Introduction Strategies are needed to curb the increasing HIV incidence in young men who
have sex with men (YMSM) and transgender women (YTGW) worldwide. We assessed the …